# Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

> **NCT03602638** · PHASE4 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Acarbose

## Key facts

- **NCT ID:** NCT03602638
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2019-05-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2018-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03602638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03602638, "Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03602638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*